Overview

A Study of VIS410 to Assess Safety and Pharmacokinetics

Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacokinetics of single escalating doses of VIS410 in healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Visterra, Inc.
Treatments:
Antibodies, Monoclonal